This program was developed by ProCE, Inc. and supported
by an educational grant from Takeda Pharmaceuticals North America, Inc.
Type 2 Diabetes and Cardiovascular Disease: A Case Based Approach Presented by:
Patrick J. Boyle, MD
Professor of Medicine
Department of Internal Medicine
University of New Mexico
Albuquerque, New Mexico
Susan A. Cornell, BS, PharmD, CDE, CDM
Assistant Director of Experiential Education
Assistant Professor, Department of Pharmacy Practice
Midwestern University, Chicago College of Pharmacy
Downers Grove, Illinois
David W. Bartels, PharmD, BCPS, CDE, FCCP
Director, Pharmacy Education Programs
Clinical Associate Professor
University of Illinois at Chicago College of Pharmacy
University of Illinois at Rockford College of Medicine
Chicago & Rockford, Illinois Goals and Objectives:
- Identify the cardiovascular risks associated with Type 2 diabetes including clinical and cost implications.
- Discuss the management of Type 2 diabetes and cardiovascular disease.
- List strategies to optimize the health and wellness of Type 2 diabetes patients.
- Analyze the results of cardiovascular outcomes studies conducted in the Type 2 diabetes population.
Faculty Disclosure:
It is the policy of ProCE to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer of any commercial product(s) discussed in an educational presentation. Dr. Bartels has disclosed the following commercial/financial relationships through Grant/Research Support and/or Consultant Sevices and/or Speakers' Bureau: Eli Lilly, Pfizer, sanofi-aventis, and Takeda. Dr. Boyle has disclosed the following commercial/financial realtionships through Grant/Research Support and/or Conultant Services and/or Speakers' Bureau: Amylin, Eli Lilly, Pfizer, and Takeda. Dr. Cornell has disclosed the following commercial/financial realtionships through Grant/Research Support and/or Consultant Services and/or Speakers' Bureau: Abbott, Bayer, LifeScan, Merck, Novo Nordisk, Pfizer, Roche, and Takeda.
Please note: The opinions expressed in this program should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical and knowledge of the professional literature. Portions of this program may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature. Target Audience:
The target audience for this program is pharmacists caring for patients with diabetes.
Fee:
Free!!
|
Macromedia Flash